In the study, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) reduced the risk of radiographic progression or death by 59% ...

Novartis said the U.S. Food and Drug Administration has approved the use of Pluvicto against a certain type of prostate cancer. The drug maker said Friday that the FDA green-lit the use of Pluvicto to ...

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

The multi-year collaboration leverages Docquity's Awareness to Advocacy (A2A) Program to expand retinal health education amongst thousands of HCPs and widen access to retinal health products With 81.5 ...

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

The Department of Health and Human Services (HHS) has filed for summary judgment in its favor regarding lawsuits brought by ...

Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing ...

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Web hosting is the foundation of your online presence, and choosing the right service can ...

TOKYO -- Swiss pharmaceutical company Novartis plans to start mass production of radiopharmaceuticals, a type of next-generation cancer treatment, in Japan in 2026, Nikkei has learned. The company ...